Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
Terconazole is an azole antifungal cream administered vaginally to treat vaginal fungal infections, primarily candidiasis. It works by disrupting fungal cell membrane synthesis through inhibition of lanosterol 14α-demethylase. The drug has been approved since 2004 and remains a standard-of-care option in gynecological care.
As LOE approaches and competitive pressure remains moderate (30%), brand teams will shift focus from growth to defending market share against generics and OTC alternatives.
Azole Antifungal
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
With zero linked job openings and approaching LOE, career opportunities on Terconazole are limited and declining. Professionals seeking growth, innovation, and career advancement should consider pipeline assets or higher-growth therapeutic areas rather than this mature, genericizing product.
Worked on TERCONAZOLE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.